Avanos Medical, Inc. (NYSE:AVNS) Short Interest Up 23.1% in January

Avanos Medical, Inc. (NYSE:AVNS) saw a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 3,218,424 shares, a growth of 23.1% from the December 31st total of 2,613,713 shares. Based on an average daily trading volume, of 597,584 shares, the days-to-cover ratio is presently 5.4 days. Currently, 7.1% of the company’s shares are short sold. Currently, 7.1% of the company’s shares are short sold. Based on an average daily trading volume, of 597,584 shares, the days-to-cover ratio is presently 5.4 days.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on AVNS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Wall Street Zen raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Finally, Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, January 26th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce”.

Avanos Medical Stock Up 0.2%

Shares of NYSE:AVNS traded up $0.03 during trading on Tuesday, reaching $13.50. 186,871 shares of the stock were exchanged, compared to its average volume of 576,651. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $17.54. The stock has a fifty day moving average of $11.92 and a two-hundred day moving average of $11.67. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.38 and a quick ratio of 1.36. The firm has a market cap of $626.44 million, a price-to-earnings ratio of -1.33 and a beta of 1.09.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.10. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The business had revenue of $177.80 million during the quarter, compared to analyst estimates of $164.50 million. During the same quarter in the previous year, the business posted $0.33 EPS. Avanos Medical’s quarterly revenue was up 4.3% on a year-over-year basis. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Research analysts anticipate that Avanos Medical will post 1.32 earnings per share for the current fiscal year.

Insider Transactions at Avanos Medical

In other news, SVP Kerr Holbrook sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total transaction of $165,000.00. Following the completion of the transaction, the senior vice president owned 83,860 shares of the company’s stock, valued at approximately $922,460. This trade represents a 15.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.64% of the company’s stock.

Hedge Funds Weigh In On Avanos Medical

Large investors have recently bought and sold shares of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Avanos Medical in the second quarter worth about $192,000. Wealth Enhancement Advisory Services LLC bought a new position in shares of Avanos Medical during the 2nd quarter valued at approximately $262,000. Squarepoint Ops LLC purchased a new stake in shares of Avanos Medical during the 2nd quarter worth approximately $1,145,000. AlphaQuest LLC raised its holdings in shares of Avanos Medical by 58.5% in the 2nd quarter. AlphaQuest LLC now owns 37,091 shares of the company’s stock worth $454,000 after purchasing an additional 13,692 shares during the period. Finally, Tributary Capital Management LLC raised its holdings in shares of Avanos Medical by 10.0% in the 2nd quarter. Tributary Capital Management LLC now owns 810,720 shares of the company’s stock worth $9,923,000 after purchasing an additional 73,518 shares during the period. 95.17% of the stock is currently owned by institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.